Abrogation of cardiomyopathy in diabetic rats by escin - possible role of NF-κβ and MCP-1
OBJECTIVE: Diabetic cardiomyopathy is one of the most common complications of diabetes. Escin may significantly inhibit myocardial damage through its NF-κβ inhibitory, antidiabetic, neuroprotective, and potent anti-inflammatory activity. Hence, the study was carried out to evaluate the effect of escin in diabetic cardiomyopathy.
METHODS: Diabetes induction was done in rats with streptozotocin. After six weeks of induction, diabetic animals were administered with escin (5, 10, and 20 mg/kg) for the next four weeks.
RESULTS: Escin prevented the progression of abnormalities in the biochemical, hemodynamic parameters and electrocardiogram. Escin also prevented the progression of abnormality in the oxidative stress parameters. The expression of NF-κβ and MCP-1 was significantly reduced with escin treatment. Furthermore, escin also prevented damage to myocardial cells and reduced collagen deposition in the cardiomyocytes.
CONCLUSION: Escin prevented the progression of cardiomyopathy in diabetic rats. Hence escin can be an alternative option for the management of diabetic cardiomyopathy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
Archives of physiology and biochemistry - 130(2024), 1 vom: 01. Jan., Seite 49-55 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Suryavanshi, Sachin V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6805-41-0 |
|---|
| Anmerkungen: |
Date Completed 31.01.2024 Date Revised 31.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/13813455.2021.1963782 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329274333 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329274333 | ||
| 003 | DE-627 | ||
| 005 | 20240131231824.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13813455.2021.1963782 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1276.xml |
| 035 | |a (DE-627)NLM329274333 | ||
| 035 | |a (NLM)34383591 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Suryavanshi, Sachin V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Abrogation of cardiomyopathy in diabetic rats by escin - possible role of NF-κβ and MCP-1 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2024 | ||
| 500 | |a Date Revised 31.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: Diabetic cardiomyopathy is one of the most common complications of diabetes. Escin may significantly inhibit myocardial damage through its NF-κβ inhibitory, antidiabetic, neuroprotective, and potent anti-inflammatory activity. Hence, the study was carried out to evaluate the effect of escin in diabetic cardiomyopathy | ||
| 520 | |a METHODS: Diabetes induction was done in rats with streptozotocin. After six weeks of induction, diabetic animals were administered with escin (5, 10, and 20 mg/kg) for the next four weeks | ||
| 520 | |a RESULTS: Escin prevented the progression of abnormalities in the biochemical, hemodynamic parameters and electrocardiogram. Escin also prevented the progression of abnormality in the oxidative stress parameters. The expression of NF-κβ and MCP-1 was significantly reduced with escin treatment. Furthermore, escin also prevented damage to myocardial cells and reduced collagen deposition in the cardiomyocytes | ||
| 520 | |a CONCLUSION: Escin prevented the progression of cardiomyopathy in diabetic rats. Hence escin can be an alternative option for the management of diabetic cardiomyopathy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Escin | |
| 650 | 4 | |a NF-κβ | |
| 650 | 4 | |a diabetic cardiomyopathy | |
| 650 | 4 | |a horse chestnut | |
| 650 | 4 | |a pentacyclic triterpenes | |
| 650 | 7 | |a Escin |2 NLM | |
| 650 | 7 | |a 6805-41-0 |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 700 | 1 | |a Kulkarni, Yogesh A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of physiology and biochemistry |d 1997 |g 130(2024), 1 vom: 01. Jan., Seite 49-55 |w (DE-627)NLM075599813 |x 1744-4160 |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:49-55 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13813455.2021.1963782 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2024 |e 1 |b 01 |c 01 |h 49-55 | ||